Plasma YKL-40 predicts 10-year cardiovascular and all-cause mortality in individuals with type 2 diabetes

Clinical Endocrinology

Volumn 79, Issue 2, 2013, Pages 185-191

  Lin, Chih Hung ^a   Li, Hung Yuan ^a   Jiang, Yi Der ^a   Chang, Tien Jyun ^a   Chuang, Lee Ming ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 39; UNCLASSIFIED DRUG; YKL 40 PROTEIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SURVIVAL;

ADIPOKINES; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LECTINS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAIWAN;

EID: 84880062776     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12015     Document Type: Article

References (33)

1. Hakala, B.E., White, C., &, Recklies, A.D., (1993) Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. Journal of Biological Chemistry, 268, 25803-25810.
2. Rehli, M., Krause, S.W., &, Andreesen, R., (1997) Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics, 43, 221-225.
3. Rathcke, C.N., &, Vestergaard, H., (2006) YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflammation Research, 55, 221-227.
4. Kucur, M., Isman, F.K., Karadag, B., et al,. (2007) Serum YKL-40 levels in patients with coronary artery disease. Coronary Artery Disease, 18, 391-396.
5. Wang, Y., Ripa, R.S., Johansen, J.S., et al,. (2008) YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scandinavian Cardiovascular Journal, 42, 295-302.
6. Rathcke, C.N., Persson, F., Tarnow, L., et al,. (2009) YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care, 32, 323-328.
7. Rathcke, C.N., Johansen, J.S., &, Vestergaard, H., (2006) YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflammation Research, 55, 53-59.
8. Nielsen, A.R., Erikstrup, C., Johansen, J.S., et al,. (2008) Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes, 57, 3078-3082.
9. Boot, R.G., van Achterberg, T.A., van Aken, B.E., et al,. (1999) Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 19, 687-694.
10. Stamler, J., Vaccaro, O., Neaton, J.D., et al,. (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 16, 434-444.
11. Haffner, S.M., Lehto, S., Ronnemaa, T., et al,. (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New England Journal of Medicine, 339, 229-234.
12. Schramm, T.K., Gislason, G.H., Kober, L., et al,. (2008) Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation, 117, 1945-1954.
13. Jiang, Y.D., Chuang, L.M., Wu, H.P., et al,. (1998) Role of an outpatient clinic in screening chronic complications of diabetes: a model for diabetes managed care. Journal of the Formosan Medical Association, 97, 521-527.
14. Levey, A.S., Stevens, L.A., Schmid, C.H., et al,. (2009) A new equation to estimate glomerular filtration rate. Annals of Internal Medicine, 150, 604-612.
15. Pan, W.H., Flegal, K.M., Chang, H.Y., et al,. (2004) Body mass index and obesity-related metabolic disorders in Taiwanese and US whites and blacks: implications for definitions of overweight and obesity for Asians. American Journal of Clinical Nutrition, 79, 31-39.
16. American Diabetes Association. (2011) Standards of medical care in diabetes-2011. Diabetes Care, 34, S11-S61.
17. Anderson, K.M., Odell, P.M., Wilson, P.W.F., et al,. (1991) Cardiovascular disease risk profiles. American Heart Journal, 121, 293-298.
18. Hiatt, W.R., (2001) Medical treatment of peripheral arterial disease and claudication. New England Journal of Medicine, 344, 1608-1621.
19. Yang, H.I., Lu, S.N., Liaw, Y.F., et al,. (2002) Hepatitis B e antigen and the risk of hepatocellular carcinoma. New England Journal of Medicine, 347, 168-174.
20. World Health Organization. (1993) International Statistical Classification of Diseases and Related Health Problem. World Health Organization, Geneva.
21. Bojesen, S.E., Johansen, J.S., &, Nordestgaard, B.G., (2011) Plasma YKL-40 levels in healthy subjects from the general population. Clinica Chimica Acta, 412, 709-712.
22. Rathcke, C.N., Raymond, I., Kistorp, C., et al,. (2010) Low grade inflammation as measured by levels of YKL-40: association with an increased overall and cardiovascular mortality rate in an elderly population. International Journal of Cardiology, 143, 35-42.
23. Johansen, J.S., Bojesen, S.E., Tybjaerg-Hansen, A., et al,. (2010) Plasma YKL-40 and total and disease-specific mortality in the general population. Clinical Chemistry, 56, 1580-1591.
24. Kastrup, J., Johansen, J.S., Winkel, P., et al,. (2009) High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. European Heart Journal, 30, 1066-1072.
25. Persson, F., Rathcke, C.N., Gall, M.A., et al,. (2012) High YKL-40 levels predict mortality in patients with type 2 diabetes. Diabetes Research and Clinical Practice, 96, 84-89.
26. Ross, R., (1999) Atherosclerosis-an inflammatory disease. New England Journal of Medicine, 340, 115-126.
27. Johansen, J.S., Jensen, B.V., Roslind, A., et al,. (2006) Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiology, Biomarkers and Prevention, 15, 194-202.
28. Mathiasen, A.B., Harutyunyan, M.J., Jorgensen, E., et al,. (2011) Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease. Scandinavian Journal of Clinical and Laboratory Investigation, 71, 439-447.
29. Ling, H., &, Recklies, A.D., (2004) The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. Biochemical Journal, 380, 651-659.
30. Brix, J.M., Hollerl, F., Koppensteiner, R., et al,. (2011) YKL-40 in type 2 diabetic patients with different levels of albuminuria. European Journal of Clinical Investigation, 41, 589-596.
31. Yasuda, T., Kaneto, H., Katakami, N., et al,. (2011) YKL-40, a new biomarker of endothelial dysfunction, is independently associated with albuminuria in type 2 diabetic patients. Diabetes Research and Clinical Practice, 91, e50-e52.
32. Rondbjerg, A.K., Omerovic, E., &, Vestergaard, H., (2011) YKL-40 levels are independently associated with albuminuria in type 2 diabetes. Cardiovascular Diabetology, 10, 54.
33. Deckert, T., Feldt-Rasmussen, B., Borch-Johnsen, K., et al,. (1989) Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia, 32, 219-226.